So if TAS is knocking out neutrophils while leronl
Post# of 148200
What if the reverse is true? What are the chances of leronlimab mitigating the effects of TAS weakening the bone marrow/stem cells and neutrophils?
Why do you think there is less killing of the neutrophils when bevacizumab is added to TAS as you've stated?